Connect with Labcorp at the American Association for Cancer Research (AACR) Annual Meeting 2024
April 5-10, 2024 | San Diego, CA | Booth 1041
Unleash the power of precision medicine at AACR 2024.
Accelerate your companion diagnostic and precision medicine programs with comprehensive testing solutions. Development of precision oncology therapeutics is complex. Labcorp has the unique ability to support you from preclinical discovery through diagnostic commercialization. We leverage our rich experience to empower you to make informed decisions at each stage.
Join us at booth 1041 to discover more about our extensive portfolio.
- Labcorp® Plasma Detect™: A tumor-informed whole genome ctDNA MRD assay. Accelerate oncology therapeutic development with fast, high confidence MRD assessment for global clinical trials.
- Drug discovery: In vitro and in vivo pharmacology efficacy models, in vivo imaging technologies, in vitro assessments and focal radiation capabilities
- Clinical development and commercialization: Biomarker discovery and strategy development, companion diagnostic development, sponsored testing and NGS kitted solutions
- Testing solutions: Streamlined CGP solutions; centralized services for hereditary, tissue, liquid and heme testing; translational research opportunities for kitted solutions and centralized services
Spotlight Theater
Date: Tuesday, April 9, 2024
Time: 10:00 a.m.
Location: Spotlight Theater A
Title: Biomarker solutions for all: Innovative solid tumor MRD detection and immune profiling solutions for advanced drug development
Speakers:
- Taylor Jensen, PhD, VP, Oncology R&D Science, Labcorp
- Mark Sausen, PhD, Executive Director, Translational Development, Labcorp
- Sarabjot Pabla, PhD, Head of Clinical and Research Bioinformatics, Labcorp
- Remond Fijneman, PhD, Principal Investigator and Associate Group Leader, Translational Gastrointestinal Oncology Group, Netherlands Cancer Institute
Oral Presentation
Date: Tuesday, April 9, 2024
Time: 3:10 PM - 3:25 PM
Location: Ballroom 6 CF - Upper Level - Convention Center
Title: Clinical validity of post-surgery circulating tumor DNA testing in stage III colon cancer patients treated with adjuvant chemotherapy: The PROVENC3 study
Speakers: Carmen Rubio Alarcon, PhD, Netherlands Cancer Institute, Amsterdam
Download posters:
| Session Date & Time | Presenting Author | Title | Details |
| Sunday, April 7 | |||
| Sunday, April 7 1:30-5:00 PM | David Draper, Yewei Xing and Scott Wise | NK cell ADCC assays: Leveraging flow cytometry and reporter cell lines for enhanced biological relevance and throughput | Track: Immunology Session: Biomarkers, Immune Monitoring and Immune Assays Abstract #83 Section: 3 |
| Sunday, April 7 1:30-5:00 PM | Hardik Parikh | Landscape of HIF-1α expression across 24,186 solid tumors using comprehensive immune profiling | Track: Molecular/Cellular Biology and Genetics Session: Cellular Stress Responses 1 Abstract #379 Section: 16 |
| Sunday, April 7 1:30-5:00 PM | Maria Fatteh (external) | Liquid biopsy-informed precision oncology clinical trial to evaluate the utility of ctDNA comprehensive genomic profiling | Track: Clinical Research Session: Circulating Nucleic Acids 1 Abstract #970 Section: 40 |
| Session Date & Time | Presenting Author | Title | Details |
| Monday, April 8 | |||
| Monday, April 8 9:00 AM - 12:30 PM | Ingrid A. Franken(external) | Molecular characterization of stage III colon cancer patients with recurrence after adjuvant chemotherapy | Track: Clinical Research Session: Predictive Biomarkers 1 Abstract #2496 Section: 43 |
| Monday, April 8 1:30-5:00 PM | Caitlin Schroyer and Shanshan Zhou | Spatial transcriptomic study of the tumor microenvironment in HNSCC | Track: Clinical Research Session: Biomarkers in Clinical Trials Abstract #3652 Section: 40 |
| Monday, April 8 1:30-5:00 PM | Li Shen (external) | Prevalence of claudin18.2 expression in gastric/gastroesophageal junction adenocarcinoma among patients in TranStar101 and TranStar102 clinical trials | Track: Clinical Research Session: Biomarkers in Clinical Trials |
| Session Date & Time | Presenting Author | Title | Details |
| Tuesday, April 9 | |||
| Tuesday, April 9 9:00 AM - 12:30 PM | Grant Hogg | Validation of an Automated, Scalable Comprehensive Genomic Profiling Assay for Hematologic Malignancies | Track: Experimental and Molecular Therapeutics Session: Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes Abstract #4628 Section: 26 |
| Tuesday, April 9 9:00 AM - 12:30 PM | Robert Summersgill | Pre-analytical characterization of cell-free DNA to enable liquid biopsy for solid tumors | Track: Clinical Research Session: Circulating Nucleic Acids 4 Abstract #5020 Section: 40 |
| Tuesday, April 9 9:00 AM -12:30 PM | I.A. Franken (external) | MEDOCC-CrEATE trial: Feasibility of measuring circulating tumor DNA after surgery to guide adjuvant chemotherapy in stage II colon cancer patients | Track: Clinical Research Session: Circulating Nucleic Acids 4 Abstract #5022 Section: 40 |
| Tuesday, April 9 9:00 AM - 12:30 PM | Amanda Harvey | Analytical Performance of Contrived Samples for Validation of Liquid Biopsy Assays | Track: Clinical Research Session: Circulating Nucleic Acids 4 Abstract #5017 Section: 40 |
| Tuesday, April 9 9:00 AM - 12:30 PM | Kerry-Ann Bright | Subcutaneous vs. Orthotopic Tumor models: A Comparative Assessment | Track: Tumor Biology Session: Models to Study Immune Cells in the Tumor Microenvironment Abstract #4204 Section: 10 |
| Tuesday, April 9 9:00 AM - 12:30 PM | Justin Snider | Analysis of tumor heterogeneity in syngeneic models; CT26.WT colon carcinoma and 4T1-Luc2-1A4 breast carcinoma in female BALB/cAnNHsd mice | Track: Tumor Biology Session: Tumor Evolution Models and Technologies Abstract #4305 Section: 13 |
| Tuesday, April 9 9:00 AM - 12:30 PM | David Draper | Investigating CAR-T cell efficacy and activation in the disseminated NALM6-luc human B-cell acute lymphoblastic leukemia model | Track: Immunology Session: Adoptive Cell Therapies 3: CAR-T Cells Abstract #4002 Section: 2 |
| Tuesday, April 9 1:30-5:00 PM | Jennifer B. Jackson | Enhanced detection of ctDNA molecular response for immunotherapy treated non-small cell lung cancer through analyses of cell-free and matched white blood cell DNA | Track: Clinical Research Session: Predictive Biomarkers 6 Abstract #6443 Section: 44 |
| Tuesday, April 9 1:30-5:00 PM | J. Lim (external collaboration) | Metabolic reprogramming enhances expansion and potency of CAR T cells (Xcelbio collaboration) | Track: Clinical Research Session: Adoptive Cellular Therapy 2 Abstract #6334 Section: 40 |
| Tuesday, April 9 1:30 PM - 5:00 PM | Sheri Barnes | Digital spatial profiling of MC38 colon carcinoma following checkpoint inhibition | Track: Tumor Biology Session: Spatial Resolution of the Tumor Microenvironment Abstract #5493 Section: 10 |
| Tuesday, April 9 1:30 PM - 5:00 PM | Yewei Xing | Generation of new oncology cell models through long-term acclimation under hypoxic and hyperbaric culture conditions | Track: Experimental and Molecular Therapeutics Session: Novel Therapeutics and Preclinical Models Abstract #6005 Section: 28 |
| Tuesday, April 9, 1:30-5:00 PM | Obada Ababneh*(external) | The predictive role of TNF-related genes in patients receiving immune checkpoint inhibitors | Track: Clinical Research Excluding Trials Session: Predictive Biomarkers 5 Abstract #6393 Section: 43 |
| Tuesday April 9, 1:30 PM - 5:00 PM | P.H.A. Wisse (external) | Comparison of FIT and ctDNA tests for detection of individuals with colorectal cancer in population based screening | Track: Prevention / Early Detection / Interception,Population Sciences Session: Biomarker Based Screening Abstract #6079 Section: 31 |
| Tuesday Apr 9, 3:10 PM - 3:25 PM Ballroom 6 CF - Upper Level - Convention Center | Carmen Rubio-Alarcón (external) | Clinical validity of post-surgery circulating tumor DNA testing in stage III colon cancer patients treated with adjuvant chemotherapy: the PROVENC3 study | Track: Clinical Research Session: Liquid Biopsy ORAL PRESENTATION |
| Session Date & Time | Presenting Author | Title | Details |
| Wednesday, April 10 | |||
| Wednesday, April 10 9:00 AM - 12:30 PM | Sarabjot Pabla | Landscape of TIGIT and PD-L1 co-expression in solid tumors | Track: Clinical Research Session: Immune Checkpoint Inhibitor Therapy Abstract #7526 Section: 42 |